ClinicalTrials.gg
Not yet recruitingNCT07435922Updated Mar 2, 2026

Evaluate Recombinant Human Serum Albumin From Oryza Sativa In Patients With Hypoalbuminemia and/or Hypovolemia Requiring Urgent Treatment

An observational study in Hypoalbuminemia and Hypovolemia, sponsored by Healthgen Biotechnology Corp.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Healthgen Biotechnology Corp. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Study summary

This study is a post-marketing, multicenter, prospective, open-label observational study. It plans to enroll approximately 2,000 patients with hypoalbuminemia and/or hypovolemia requiring urgent treatment who are scheduled to receive at least one dose of Recombinant Human Albumin from Oryza Sativa. The study does not interfere with clinical diagnosis and treatment; the use of the study drug is solely determined by the attending physician based on the patient's condition and clinical guidelines.

Study data will be collected during the patient's participation in the study, including baseline characteristics, medical history, concomitant medications, records of study drug administration and reasons for use, serum albumin levels (baseline and end of treatment), adverse events (AEs), adverse drug reactions (ADRs), serious adverse events (SAEs), and adverse events of special interest (AESIs). The follow-up period will primarily be conducted via telephone.

The primary endpoint of the study is the incidence of all adverse drug reactions (ADRs). Secondary endpoints include the incidence of all adverse events (AEs), the incidence of AEs by severity, the incidence of serious adverse events (SAEs), the incidence of adverse events of special interest (AESIs), and the incidence of AEs leading to dose interruption, dose reduction, discontinuation, or death related to Recombinant Human Albumin Injection from Oryza Sativa. Efficacy evaluations include changes in serum albumin concentration before and after treatment and assessment of volume restoration.

02

Conditions studied

  • Hypoalbuminemia
  • Hypovolemia
03

In context

Hypoalbuminemia

41 studies on the registry are indexed under Hypoalbuminemia; 9 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 160 across 15 observational studies indexed under Hypoalbuminemia.

Browse Hypoalbuminemia studies →

Lead sponsor

Healthgen Biotechnology Corp. is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients With Hypoalbuminemia and/or Hypovolemia Requiring Urgent Treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years, male or female.
  • Hypoalbuminemia and/or hypovolemia requiring urgent treatment.
  • Agree to participate in this study and sign a written form by the subject themselves or their legal representative (guardian).
  • In real-world clinical practice, the attending physician has decided and planned to administer at least one dose of human albumin injection.

Exclusion criteria

Exclusion Criteria:

  • Known allergy to the active ingredients or any of this product.
  • Any medical condition that, in the investigator's judgment, may significantly increase the subject's risk or interfere with their participation in and completion of this study.
  • Participation in any other clinical trial of a drug at the time of enrollment in this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Recombinant Human Serum Albumin From Oryza Sativa

    Drug: Recombinant Human Serum Albumin From Oryza Sativa

Interventions

  • DrugRecombinant Human Serum Albumin From Oryza Sativa

    The treatment of the study drug will be solely determined by the attending physician based on the patient's condition and clinical guidelines.

06

What researchers measure

Primary outcomes

  1. incidence of all adverse drug reactions

    Time frame: During treatment to a month after treatment

Secondary outcomes

  1. The incidence of all adverse events (AEs)

    Time frame: During treatment to a month after treatment

  2. The incidence of serious adverse events.

    Time frame: During treatment to a month after treatment

  3. The incidence of adverse events of special interest (AESIs).

    Time frame: During treatment to a month after treatment

  4. The incidence of AEs leading to dose interruption, dose reduction, discontinuation, or death related to Recombinant Human Albumin Injection from Oryza Sativa.

    Time frame: During treatment to a month after treatment

  5. Changes from baseline in serum albumin concentration.

    Time frame: One day after the end of treatment

07

Study locations

1 site
  • Hebei medical university third hosipital
    Shijiazhuang, Hebei, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for Sep 2026, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2026
First posted
Feb 27, 2026
StartEst.
Feb 24, 2026
Primary completionEst.
Sep 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07435922
Lead sponsor
Healthgen Biotechnology Corp.
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Feb 24, 2026 (estimated)
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 2, 2026

Study contacts

Yuemin Lan, MD
Contact
nanyuemin@163.com
+86-185 3311 2266

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion